ATNM · ISSUER CIK 1388320
Actinium Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 7 Actinium Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Oct 16, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 202617:11 | Oct 14, 2026 | ATNM | Chief Financial Officer | A · Grant | — | +250,000 | 250,000 | New | — | ||
| Sep 4, 202617:00 | Sep 2, 2026 | ATNM | Director | A · Grant | — | +61,600 | 62,357 | +8137% | — | ||
| Sep 4, 202617:00 | Sep 2, 2026 | ATNM | Director | A · Grant | — | +62,800 | 63,300 | +12560% | — | ||
| Sep 4, 202617:00 | Sep 2, 2026 | ATNM | Director | A · Grant10b5-1 | — | +18,000 | 18,000 | New | — | ||
| Sep 4, 202617:00 | Sep 2, 2026 | ATNM | Chief Executive Officer, Director | A · Grant | — | +1,780,874 | 1,965,355 | +965% | — | ||
| Sep 4, 202617:00 | Sep 2, 2026 | ATNM | Director | A · Grant | — | +62,800 | 63,116 | +19873% | — | ||
| Sep 4, 202617:00 | Sep 2, 2026 | ATNM | Director | A · Grant | — | +61,600 | 61,600 | New | — |